Table 3. G protein coupled receptors (GPCRs) that were down-regulated in day 20 compared to day 4 Ebs. GPCRs that showed a greater than 4 fold decrease in RNA level are listed. The genes are categorized into their family (based roughly on IUPHAR categories)  and their fold change is indicated. The data represent the average of the results from two independent experiments.

Table 2. G protein coupled receptors (GPCRs) that were upregulated in day 20 compared to day 4 Ebs

Table 2. Set of 81 genes modulated by the deregulation HIF1A in non-malignant liver tissue

Table 7. List of Some Genes That Are Expressed Differentially Between Circulating Endothelial Cells and CD19-Positive Cells From Patients With Chronic Lymphocytic Leukemia

Table 6. List of Some Genes That Are Expressed Differentially Between Circulating Endothelial Cells From Patients With Chronic Lymphocytic Leukemia and From Normal Controls

Table 1. Fifteen QRT–PCR validated genes shown to be differentially expressed among BRCA1  BRCA2  and BRCAX pools  and MMC responsive in affected carrier pools but not in healthy controls.

SuppTable 1. List of genes and their associated significance levels from three different analyses.

Table 2. Method 2 (DLDA: diagonal linear discriminant analysis) analysis of SCLC (small cell lung carcinoma) predictor genes

Table 3. Method 2 (DLDA: diagonal linear discriminant analysis) analysis of leukemia/lymphoma predictor genes

Table 1. Average differential expression of Bcl-2 family members

Table 2. Gene signature of 42 genes which predicts outcome in neuroblastoma across independent data sets

Table 1. Gene expression profiling of Jurkat T cells treated with p-NO-ASA (the para isomer of NO-donating aspirin

SuppTable 1. Full list of genes found differentially expressed between the two groups of patients with p<0.01 (Bayesian moderated t-test). FC refers to fold change as of the average normalised-intensity for that gene in N-SL group compared to P-F group.

Figure 1b: Top 50 genes with increased expression in progressive fibrotic (P-F) disease compared to N-SL group  ranked by fold change